L
Loren Laine
Researcher at University of Southern California
Publications - 16
Citations - 3570
Loren Laine is an academic researcher from University of Southern California. The author has contributed to research in topics: Diclofenac & Etoricoxib. The author has an hindex of 15, co-authored 16 publications receiving 3259 citations. Previous affiliations of Loren Laine include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials
Colin Baigent,Neeraj Bhala,Jonathan Emberson,A Merhi,S. Abramson,Nadir Arber,John A. Baron,Claire Bombardier,Christopher P. Cannon,Michael E. Farkouh,Garret A. FitzGerald,Paul E. Goss,Heather Halls,Ernest T. Hawk,Christopher J. Hawkey,C H Hennekens,Marc C. Hochberg,Lisa Holland,Patricia M. Kearney,Loren Laine,Angel Lanas,Peter Lance,Andreas Laupacis,Jim C. Oates,Carlo Patrono,Thomas J. Schnitzer,Scott D. Solomon,Peter Tugwell,Kate Wilson,Janet Wittes,O. Adelowo,P. Aisen,Abdulaziz A Al-Quorain,Roy D. Altman,George L. Bakris,H. Baumgartner,C. Bresee,M. Carducci,D. M. Chang,C. T. Chou,D. Clegg,M. Cudkowicz,L. Doody,Y. El Miedany,Claire Falandry,J. Farley,Leslie G. Ford,M. Garcia-Losa,M. Gonzalez-Ortiz,M. Haghighi,M. Hala,T. Iwama,Zrinka Jajić,David J. Kerr,H. S. Kim,C.-H. Köhne,B. K. Koo,Barbara K. Martin,Curtis L. Meinert,N. Muller,G. Myklebust,D. Neustadt,R. Omdal,S. Ozgocmen,A. Papas,Paola Patrignani,F. Pelliccia,V. Roy,I. Schlegelmilch,Asad Umar,O. Wahlstrom,F. Wollheim,S. Yocum,X. Y. Zhang,E. Hall,Patricia McGettigan,R Midgley,R. A. Moore,R. Philipson,Sean P. Curtis,Alise S. Reicin,John H. Bond,Ami R. Moore,M. Essex,J. Fabule,B. Morrison,Leslie Tive,Kelly Davies,F. Yau +88 more
TL;DR: Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making.
Journal ArticleDOI
ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use
Neena S. Abraham,Mark A. Hlatky,Elliott M. Antman,Deepak L. Bhatt,David J. Bjorkman,Craig Clark,Curt D. Furberg,David A. Johnson,Charles J. Kahi,Loren Laine,Kenneth W. Mahaffey,Eamonn Martin Quigley,James M. Scheiman,Laurence S. Sperling,Gordon F. Tomaselli +14 more
TL;DR: The ACCCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines focused on reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use.
Journal ArticleDOI
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P. Cannon,Sean P. Curtis,Garret A. FitzGerald,Henry Krum,Amarjot Kaur,James A. Bolognese,Alise S. Reicin,Claire Bombardier,Michael E. Weinblatt,Désirée van der Heijde,Erland Erdmann,Loren Laine +11 more
TL;DR: Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.
Journal ArticleDOI
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Neena S. Abraham,Mark A. Hlatky,Elliott M. Antman,Deepak L. Bhatt,David J. Bjorkman,Craig Clark,Curt D. Furberg,David A. Johnson,Charles J. Kahi,Loren Laine,Kenneth W. Mahaffey,Eamonn Martin Quigley,James M. Scheiman,Laurence S. Sperling,Gordon F. Tomaselli +14 more
TL;DR: The reader should view the expert consensus document as the best attempt of the ACCF and document cosponsors to inform clinical practice in areas where rigorous evidence may not yet be available.
Journal ArticleDOI
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
TL;DR: There were significantly fewer upper gastrointestinal clinical events with the COX-2 selective inhibitor etoricoxib than with the traditional NSAID diclofenac due to a decrease in uncomplicated events, but not in the more serious complicated events.